Pfizer Inc Stock Performance
| PFE Stock | USD 25.39 0.03 0.12% |
The company holds a Beta of 0.77, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pfizer's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pfizer is expected to be smaller as well. Pfizer Inc has an expected return of -0.14%. Please make sure to check Pfizer Inc treynor ratio, as well as the relationship between the kurtosis and day median price , to decide if Pfizer Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pfizer Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's technical and fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.12) | Five Day Return (3.28) | Year To Date Return (14.60) | Ten Year Return (13.29) | All Time Return 3 K |
Forward Dividend Yield 0.0654 | Payout Ratio 0.9016 | Last Split Factor 1054:1000 | Forward Dividend Rate 1.68 | Dividend Date 2024-03-01 |
| Pfizer dividend paid on 1st of March 2024 | 03/01/2024 |
1 | Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results | 03/28/2024 |
2 | Contraceptive Market Projected to Reach 119.89 billion by 2030 - Exclusive Report by 360iResearch | 04/03/2024 |
3 | 20 Most Populated Counties in the US | 04/08/2024 |
4 | ChatGPT Was Given 20K To Invest In Stocks and Crypto -- How It Made 2,000 in a Month | 04/09/2024 |
5 | Leading Hearing Aid Innovator Signia Named a Winner in the 2024 Excellence in Customer Service Awards | 04/10/2024 |
6 | Covid vaccines not linked to fatal heart problems in young people, CDC finds | 04/11/2024 |
7 | US drug shortages hit all time, pharmacists warn | 04/12/2024 |
8 | Acquisition by Albert Bourla of tradable shares of Pfizer subject to Rule 16b-3 | 04/15/2024 |
| Begin Period Cash Flow | 416 M | |
| Total Cashflows From Investing Activities | -32.3 B |
Pfizer |
Pfizer Relative Risk vs. Return Landscape
If you would invest 2,789 in Pfizer Inc on January 20, 2024 and sell it today you would lose (250.00) from holding Pfizer Inc or give up 8.96% of portfolio value over 90 days. Pfizer Inc is generating negative expected returns assuming volatility of 1.3332% on return distribution over 90 days investment horizon. In other words, 11% of stocks are less volatile than Pfizer, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Pfizer Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pfizer's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pfizer Inc, and traders can use it to determine the average amount a Pfizer's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.107
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PFE |
Estimated Market Risk
| 1.33 actual daily | 11 89% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pfizer is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pfizer by adding Pfizer to a well-diversified portfolio.
Pfizer Fundamentals Growth
Pfizer Stock prices reflect investors' perceptions of the future prospects and financial health of Pfizer, and Pfizer fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pfizer Stock performance.
| Return On Equity | 0.0235 | ||||
| Return On Asset | 0.0155 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | (0.50) % | ||||
| Current Valuation | 207.98 B | ||||
| Shares Outstanding | 5.66 B | ||||
| Price To Earning | 9.48 X | ||||
| Price To Book | 1.65 X | ||||
| Price To Sales | 2.50 X | ||||
| Revenue | 58.5 B | ||||
| Gross Profit | 66.23 B | ||||
| EBITDA | 10.53 B | ||||
| Net Income | 2.13 B | ||||
| Cash And Equivalents | 2.85 B | ||||
| Cash Per Share | 6.44 X | ||||
| Total Debt | 75.04 B | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 1.59 X | ||||
| Book Value Per Share | 15.77 X | ||||
| Cash Flow From Operations | 8.7 B | ||||
| Earnings Per Share | 0.37 X | ||||
| Market Capitalization | 145.47 B | ||||
| Total Asset | 226.5 B | ||||
| Retained Earnings | 118.35 B | ||||
| Working Capital | (4.46 B) | ||||
| Current Asset | 43.8 B | ||||
| Current Liabilities | 29.4 B | ||||
About Pfizer Performance
To evaluate Pfizer Inc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Pfizer generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Pfizer Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Pfizer Inc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Pfizer's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 127.31 | 120.94 | |
| Return On Tangible Assets | 0.02 | 0.02 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.02 | 0.02 |
Things to note about Pfizer Inc performance evaluation
Checking the ongoing alerts about Pfizer for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pfizer Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pfizer Inc generated a negative expected return over the last 90 days | |
| About 70.0% of the company shares are owned by institutional investors | |
| On 1st of March 2024 Pfizer paid $ 0.42 per share dividend to its current shareholders | |
| Latest headline from zacks.com: Acquisition by Albert Bourla of tradable shares of Pfizer subject to Rule 16b-3 |
- Analyzing Pfizer's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pfizer's stock is overvalued or undervalued compared to its peers.
- Examining Pfizer's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pfizer's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pfizer's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pfizer's stock. These opinions can provide insight into Pfizer's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.